Eli Lilly and Company

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Abcellera Biologies Inc.

Baxter Biotech Technology Sarl

Abcellera Biologics Inc.

Christopher Carl Frye

Radmila Micanovic

Barney S Graham

Charles L Hershberger

Julian Davies

Bryan Edward Jones

John Mascola

Wei Shi

Lingshu Wang

Qing Chai

Kizzmekia S Corbett

Julie Ledgerwood

Lihua Huang

Michael Dewain Kalos

Jeffrey Streetman Boyles

Jörg Hendle

Krithika Muthuraman

John Michael Sauder

Kathryn Westendorf

Olubukola Abiona

Anna Pustilnik

Wing-pui Kong

Kevin Jepson

Yi Zhang

Denisa Foster

Helen Kotanides

Ester Falconer

Stephanie Lynn Sandefur

Stefanie Zentelis

Ganapathy Gopalrathnam

Haichao Zhang

Wolfgang Glaesner

Beth Ann Strifler

John Michael Beals

Elaine A Best

Shun Li

Radhakrishnan Rathnachalam

Jing Shang

The present invention relates to antibodies that bind to human CD137 and display agonist activity, and are useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Methods of treating cancer using anti-CD137 antibodies

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-coronavirus antibodies and methods of use

The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Anti-CD137 antibodies

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

Muteins of fibroblast growth factor 21

The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Methods of reducing the levels of protoporphyrin IX in recombinant

The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.

Bovine dipeptidylaminopeptidase 1

Growing community of inventors

Bargersville, IN, United States of America

Christopher Carl Frye